# SenesTech, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/SenesTech, Inc.).

## Overview

SenesTech, Inc. develops and commercializes fertility-control products for managing rat and mouse populations. Its portfolio includes ContraPest and the Evolve line, which are sold in the United States and through international distributors, with operations centered in Surprise, Arizona.

## Products & services

• ContraPest fertility control for rats
• Evolve Rat rodent fertility control
• Evolve Mouse rodent fertility control
• Regulatory registration and product labeling support
• Distributor-led international commercialization

- **ContraPest** (35%) — Liquid fertility-control product for rat population management.
- **Evolve Rat** (40%) — Fertility-control product for rat control across commercial channels.
- **Evolve Mouse** (20%) — Fertility-control product designed for mouse population management.
- **International distribution and support** (5%) — Sales through overseas distributors and related commercialization support.

- ContraPest fertility control for rats
- Evolve Rat rodent fertility control
- Evolve Mouse rodent fertility control
- Regulatory registration and product labeling support
- Distributor-led international commercialization

## Customers

SenesTech sells to end users that need ongoing rodent population control, including pest management professionals, retailers, and commercial or institutional facilities. The products are also relevant to agricultural and food-related operators where rodents threaten stored goods, infrastructure, and biosecurity. Adoption depends on customers seeking non-lethal, fertility-based alternatives to traditional rodenticides.

- **Pest management professionals** (primary) — Buy Evolve and ContraPest for field use in recurring rodent-control programs.
- **Retail and e-commerce buyers** (primary) — Purchase rodent fertility-control products through online retail channels for self-directed use.
- **Commercial and institutional facilities** (secondary) — Use the products to manage rats and mice in buildings, campuses, and operations sites.
- **Agricultural and food-related operators** (secondary) — Buy to reduce rodent-driven contamination, feed loss, and infrastructure damage.
- **International distributors** (emerging) — Distribute products into foreign markets after local regulatory and channel setup.

- Pest management professionals buying tools for recurring rodent control
- Retail customers seeking non-lethal rodent management products
- Commercial and institutional sites with chronic rat or mouse pressure
- Agricultural and food operators exposed to contamination and damage
- International distributors that localize access to new markets

## Geography

SenesTech is headquartered and manufactures in Surprise, Arizona, and its products are sold across the United States. ContraPest is registered in all 50 states plus U.S. territories, while Evolve Rat and Evolve Mouse have more limited state registrations and are also marketed internationally through distributors. Geography matters because regulatory approval, labeling, and distributor relationships determine where each product can be sold.

- Headquarters and manufacturing are in Surprise, Arizona
- Primary revenue base is the United States
- ContraPest is registered nationwide plus U.S. territories
- Evolve products have narrower state coverage than ContraPest
- International sales depend on local distributors and approvals

## Strategy

SenesTech is focused on scaling its Evolve product family, expanding e-commerce and retail reach, and strengthening distribution through pest-management professionals and partners. It also seeks additional regulatory approvals and international market access, while improving manufacturing efficiency to support broader commercialization. These priorities are intended to widen adoption of fertility-control rodent management and improve the economics of the business model.

- **Expand Evolve commercialization** (short-term) — Evolve is the main growth engine and broadens the company's addressable market.
- **Broaden regulatory coverage** (medium-term) — State and foreign approvals determine where products can be sold.
- **Improve operating efficiency** (short-term) — Manufacturing throughput and supplier economics affect scalability and margins.
- **Build channel partnerships** (medium-term) — Partners help reach customers faster and support market education.

- Scale the Evolve product family across more channels
- Expand e-commerce and retail availability
- Grow professional pest-management distribution
- Pursue additional regulatory approvals in the U.S. and abroad
- Improve manufacturing efficiency and supplier reliability
- Use strategic partnerships to accelerate market adoption

## Risks

SenesTech depends on market acceptance of a relatively new fertility-control category, so adoption risk is central to the business. Regulatory approvals, channel execution, and supply continuity are also important because the products cannot be sold broadly without registrations and reliable manufacturing inputs. As a small commercial-stage company, it also faces financing, personnel, and product-liability risks typical of early commercialization businesses.

- **Commercialization and market acceptance risk** [high] — Revenue depends on customers choosing fertility control over traditional rodenticides.
- **Regulatory approval risk** [high] — Products require state and foreign registrations before they can be sold in many markets.
- **Supply chain and manufacturing disruption** [medium] — The company relies on third-party ingredients and a single manufacturing site.
- **Financing and liquidity risk** [high] — Commercial-stage losses and limited revenue can require external capital.
- **Product misuse and liability risk** [medium] — Off-label or improper use could trigger claims, investigations, or reputational damage.

- Customer adoption may be slower than expected for fertility-control products
- State and foreign regulatory approvals can limit market access
- Supply interruptions could disrupt manufacturing and sales
- International expansion depends on third-party distributors and local rules
- Additional financing may be needed if sales growth lags operating needs

## Accounting

Inventory valuation is a key accounting estimate because demand for a niche product line can change quickly and excess stock may require write-downs. Revenue is also sensitive to commercialization timing, channel mix, and product availability, while stock-based compensation and financing transactions can materially affect reported results for a small public company. Investors should also watch for judgments around held-to-maturity investments, property and equipment, and any future impairment or reserve issues as the business scales.

- **Inventory valuation** — Can create write-downs that reduce gross profit and earnings
- **Revenue recognition** — Can shift quarterly revenue and comparability
- **Stock-based compensation** — Raises operating expenses without immediate cash outflow
- **Held-to-maturity investments** — Changes cash deployment and reported non-operating income

- Inventory valuation depends on demand forecasts and obsolescence estimates
- Revenue timing can vary with channel mix and product availability
- Stock-based compensation affects operating expense and net loss
- Held-to-maturity investments affect cash and interest income presentation
- Property and equipment and facility build-out may create depreciation burden

---

*Last updated: 2026-04-29T04:57:59.171968+00:00*